Matt Cooper, CEO of Carmenta Bioscience. Matt was recruited to lead Carmenta when everything was on a downslope: venture capital, early stage investment, diagnostics and biotech interest. He spent a year understanding the problem and was able to attract more capital than he needed. Eighteen months after raising a seed round, with only one full time employee -- Matt -- he sold the company. Hear his story of success.
Matthew Cooper, Ph.D., is currently the Chief Scientific Officer of Progenity, a large diagnostics company that recently acquired Carmenta Bioscience, at which Matthew was CEO and founder. He also serves on the board of directors for the Preeclampsia Foundation, a patient advocacy group with the mission to reduce maternal and infant illness and death due to preeclampsia and other hypertensive disorders of pregnancy. Matthew also serves as the lead of StartX Med, an incubator for Stanford biomedical spin-outs, and is also an advisor to SPARK, the translational medicine program at Stanford University School of Medicine. Previously, Matthew served as the founding Chief Scientific Officer of Syapse, a precision medicine software company, as well as executive roles at Roche and Biogen Idec. Matthew has dual MBAs from Columbia Business School and the Berkeley Haas School of Business, a Ph.D. in Toxicology (University of Kentucky), and B.S. in Chemistry (University of Tulsa). Matthew serves on the board of directors and scientific advisory board of several biotechnology and digital health start-ups. Tickets